Lymphoplasmacytic Infiltration of the Liver in Pregnancy
Lymphoplasmacytic infiltration of the liver in a 19-week pregnant patient most likely indicates autoimmune hepatitis (AIH) and requires immediate evaluation with liver biochemistry, autoimmune serologies, and immunoglobulin levels to guide treatment decisions that could affect both maternal and fetal outcomes.
What is Lymphoplasmacytic Infiltration?
Lymphoplasmacytic infiltration refers to the accumulation of lymphocytes and plasma cells within the liver tissue, predominantly in the portal areas. This histological pattern is the hallmark feature of autoimmune hepatitis 1, 2.
According to the 2025 EASL guidelines, a predominantly portal lymphoplasmacytic infiltrate with more than mild interface hepatitis and/or more than mild lobular hepatitis (in the absence of other liver disease features) is classified as "likely AIH" 1. This represents the most specific histological signature for this condition.
Clinical Significance at 19 Weeks Gestation
Immediate Concerns
The finding at 19 weeks gestation is particularly significant because:
- AIH can progress rapidly if untreated, leading to acute liver failure, which carries high maternal and fetal mortality
- Second trimester timing allows for diagnostic workup and treatment initiation before the third trimester complications unique to pregnancy develop
- Differentiation is critical from pregnancy-specific liver diseases that typically occur later (third trimester/postpartum) 3
Diagnostic Workup Required
You must immediately obtain:
- Liver biochemistry: AST, ALT, alkaline phosphatase, bilirubin
- Autoimmune serologies: ANA, anti-smooth muscle antibody, anti-LKM1, anti-SLA/LP
- Immunoglobulins: Elevated IgG is characteristic of AIH
- Viral hepatitis panel: HBV, HCV to exclude viral causes
- Review the complete pathology report for interface hepatitis, lobular hepatitis, and portal-based fibrosis 1
Differential Diagnosis Considerations
While AIH is most likely, lymphoplasmacytic infiltration can occasionally be seen in:
- Reactive lymphoid hyperplasia (pseudolymphoma): Extremely rare, typically presents as focal lesions rather than diffuse infiltration, and is benign 4
- Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: Would present with systemic symptoms, IgM monoclonal protein, and bone marrow involvement 5
- Age-related changes: Mild periportal lymphocytic infiltration increases with age but would not be significant at 19 years old 6
The pregnancy context and predominantly portal lymphoplasmacytic pattern strongly favor AIH over these alternatives.
Management Implications
Treatment Considerations
If AIH is confirmed:
- Corticosteroids (prednisone) are safe in pregnancy and should be initiated promptly to prevent disease progression
- Azathioprine can be continued or added as it is considered compatible with pregnancy
- Untreated AIH poses greater risk to mother and fetus than treatment-related risks 3
Monitoring Strategy
- Serial liver biochemistry every 2-4 weeks initially to assess treatment response
- Distinguish from pregnancy-specific liver diseases that emerge in third trimester (HELLP syndrome, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy) 3
- Liver biopsy is rarely needed during pregnancy unless it will change management, given procedural risks 3
Critical Pitfalls to Avoid
- Do not delay treatment waiting for complete serological workup if clinical and histological features strongly suggest AIH
- Do not assume this is a pregnancy-specific condition at 19 weeks—pregnancy-unique liver diseases typically occur in third trimester or postpartum 3
- Do not dismiss as benign age-related changes in a young pregnant patient with documented lymphoplasmacytic infiltration
- Do not confuse with reactive lymphoid hyperplasia, which presents as focal nodular lesions mimicking HCC, not diffuse portal inflammation 4
Prognostic Considerations
Untreated AIH can progress to cirrhosis, acute liver failure, and death, directly impacting both maternal mortality and fetal outcomes. With appropriate immunosuppressive therapy, most patients achieve biochemical and histological remission 1. The goal is to prevent progression while safely maintaining the pregnancy, which is achievable with standard AIH treatment regimens that are pregnancy-compatible 3.